Head-To-Head Comparison: CollPlant Biotechnologies (NASDAQ:CLGN) & United Health Products (OTCMKTS:UEEC)

United Health Products (OTCMKTS:UEEC) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.

Profitability

This table compares United Health Products and CollPlant Biotechnologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
United Health Products	N/A	N/A	-600.31%
CollPlant Biotechnologies	-70.58%	-24.74%	-20.90%

Risk and Volatility

United Health Products has a beta of -0.37, suggesting that its stock price is 137% less volatile than the S&P 500. Comparatively, CollPlant Biotechnologies has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500.

Earnings & Valuation

This table compares United Health Products and CollPlant Biotechnologies’ gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Health Products	$40,000.00	939.69	-$2.62 million	N/A	N/A
CollPlant Biotechnologies	$10.62 million	4.83	-$7.02 million	($0.68)	-6.59

United Health Products has higher earnings, but lower revenue than CollPlant Biotechnologies.

Analyst Ratings

This is a summary of current ratings and price targets for United Health Products and CollPlant Biotechnologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Health Products	0	0	0	0	N/A
CollPlant Biotechnologies	0	0	1	1	3.50

CollPlant Biotechnologies has a consensus target price of $11.00, indicating a potential upside of 145.54%. Given CollPlant Biotechnologies’ higher possible upside, analysts plainly believe CollPlant Biotechnologies is more favorable than United Health Products.

Institutional and Insider Ownership

0.1% of United Health Products shares are owned by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are owned by institutional investors. 1.5% of United Health Products shares are owned by insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

CollPlant Biotechnologies beats United Health Products on 8 of the 12 factors compared between the two stocks.

About United Health Products

United Health Products, Inc. develops, manufactures, and markets hemostatic gauze products for the healthcare and wound care sectors in the United States. The company offers HemoStyp hemostatic gauze products to absorb exudate/drainage from superficial wounds, as well as helps in controlling bleeding. It serves hospitals and surgery centers, clinics and physicians, military medical care providers, hemodialysis centers, nursing homes and assisted living, and veterinary hospitals; and EMS, fire departments, and other first responders, as well as dental, oral, and maxillofacial surgery offices. The company was formerly known as United EcoEnergy Corp. and changed its name to United Health Products, Inc. in September 2010. United Health Products, Inc. was incorporated in 1997 and is headquartered in Mount Laurel, New Jersey.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.